BCM
MRNS

BlueCrest Capital Management’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

BlueCrest Capital Management’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-8,122
Closed -$124K – 1900
2018
Q1 		$124K Buy
+8,122
New +$193K ﹤0.01% 1335

Other funds holding MRNS

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TBC
Three Bays Capital Boston, Massachusetts $848M AUM 7.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlueCrest Capital Management's MRNS Position: Q2 2018 in Review

BlueCrest Capital Management sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q2 2018, closing a stake of 8,122 shares — an estimated $124K sold.

BlueCrest Capital Management first reported a position in MRNS in Q1 2018 and held it in 1 quarter. The position peaked at $124K in Q1 2018. 73 funds tracked by Wall St. Rank hold MRNS as of Q2 2018.

  • BlueCrest Capital Management reported no remaining Marinus Pharmaceuticals, Inc position as of Q2 2018 after selling out during the quarter.
  • BlueCrest Capital Management sold 8,122 Marinus Pharmaceuticals, Inc shares in Q2 2018, an estimated $124K.
  • BlueCrest Capital Management first reported a position in Marinus Pharmaceuticals, Inc in Q1 2018 and held it in 1 quarter.
  • BlueCrest Capital Management's Marinus Pharmaceuticals, Inc position peaked at $124K in Q1 2018.
  • 73 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q2 2018.

Based on BlueCrest Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.